J&J uncorks new Tremfya data in ulcerative colitis as its rival awaits an FDA decision
While J&J’s Janssen previously reported that roughly 60% of moderate to severe ulcerative colitis patients responded to an IV formulation of Tremfya, the company’s now suggesting that a follow-on subcutaneous dose was able to boost response.
Just over half of patients who received a 200 mg SC dose of Tremfya after not initially responding to the IV version eventually showed a response, Janssen announced on Monday. Patients received the SC dose after receiving either 200 mg or 400 mg of IV Tremfya.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.